Eli Lilly and (LLY) Receiving Somewhat Favorable News Coverage, Study Finds
Media stories about Eli Lilly and (NYSE:LLY) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eli Lilly and earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.8621807458078 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Autoimmune Disease Therapeutics Market Analysis, a Size nd Forecast Report 2016-2026 (mynewsdesk.com)
- Eli Lilly: Can Sales Grow Without M&A? (finance.yahoo.com)
- FY2019 EPS Estimates for Eli Lilly and Company (LLY) Decreased by Analyst (americanbankingnews.com)
- Novo’s semaglutide beats Lilly’s dulaglutide in late-stage study in type 2 diabetics; shares ahead 3% (seekingalpha.com)
- Drug companies are growing less generous in helping patients pay for meds – Los Angeles Times (latimes.com)
A number of research analysts have recently issued reports on the stock. Berenberg Bank restated a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. Sanford C. Bernstein restated an “outperform” rating and issued a $88.00 price target on shares of Eli Lilly and in a research report on Sunday, May 21st. TheStreet downgraded shares of Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. BMO Capital Markets restated an “underperform” rating and issued a $73.00 price target on shares of Eli Lilly and in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. downgraded shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a research report on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Hold” and a consensus price target of $88.27.
Shares of Eli Lilly and (NYSE LLY) traded down 0.94% during mid-day trading on Friday, reaching $77.07. 4,061,282 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $82.39 and a 200 day moving average of $81.90. The firm has a market capitalization of $81.31 billion, a P/E ratio of 33.35 and a beta of 0.34. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.86 earnings per share. On average, analysts forecast that Eli Lilly and will post $4.16 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.70%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio is currently 90.04%.
In other Eli Lilly and news, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the transaction, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Michael J. Harrington sold 22,833 shares of the firm’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock valued at $55,845,287 in the last three months. Insiders own 0.20% of the company’s stock.
WARNING: “Eli Lilly and (LLY) Receiving Somewhat Favorable News Coverage, Study Finds” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/19/eli-lilly-and-lly-receiving-somewhat-favorable-news-coverage-study-finds.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.